Swedencare AB (publ) (SECARE) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the presentation of SwedenCare's half-year report, led by our CEO Håkan Lagerberg and CFO Jenny Graflind. And we are pleased to have our European CCO Laszlo Varga joining us with the presentation during today's webinar. And as usual, we will have a Q&A after the presentation, so please raise your hand if you have any questions. Over to you, Jenny and Håkan. Thank you so much, Emma. A warm welcome to everyone joining this call. Q2 2025 highlights, sales increased 3% and primarily affected a lot with negative effects, as you all know, due to low sales growth. Organic growth, 7% increase compared to last quarter. But definitely a disappointment for us since we thought we would be reaching the double-digit goal that we have. And I will explain that a bit later. But main driver for not reaching it was a big box order that was scheduled to go out in Q2, mid-Q2. But due to not caused by us, it was up to the customer to draw the order. It started drawing out in 1st of July. Organic, yeah, organic growth. And then resulting in 19% operative EBITDA, also lower than where we want to be and mainly affected by the Amazon transition of the NatureVet account. And Jenny will go through that in detail. And also, of course, if we would have had that additional order, that would have been a good margin boost also for the quarter. Coming back to the tariffs, nothing much has happened despite all the talks, but of course creating some turmoil and discussions with customers. But as we have explained, we have local manufacturing and local sales. So we are not heavily impacted in any case. Of course, we have had some discussions with our Vetio North customers since being produced in Canada and lots of the sales go to US customers, but we have a good setup and good plans. So regar...